Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.

Autor: Hafez G; Department of Pharmacology, Faculty of Pharmacy, Altinbas University, Istanbul, Turkey., Malyszko J; Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland., Golenia A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland., Klimkowicz-Mrowiec A; Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Cracow, Poland., Ferreira AC; Nephrology Department, Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal.; Universidade Nova de Lisboa-Faculdade de Ciências Médicas-Nephology, Lisbon, Portugal., Arıcı M; Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Bruchfeld A; Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.; Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden., Nitsch D; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK., Massy ZA; Paris-Saclay University, UVSQ, Inserm, Clinical Epidemiology Team, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France.; Department of Nephrology, Ambroise Paré University Medical Center, APHP, Paris, France., Pépin M; Department of Nephrology, Ambroise Paré University Medical Center, APHP, Paris, France.; Department of Geriatrics, Ambroise Paré University Medical Center, APHP, Boulogne-Billancourt, France., Capasso G; Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.; Biogem Research Institute, Ariano Irpino, Italy., Mani LY; Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Liabeuf S; Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, France.; MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.
Jazyk: angličtina
Zdroj: Clinical kidney journal [Clin Kidney J] 2023 Sep 18; Vol. 16 (12), pp. 2378-2392. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).
DOI: 10.1093/ckj/sfad239
Abstrakt: There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.
Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
(© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje